Cargando…

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor

BACKGROUND: Granulocyte–colony-stimulating factor (G-CSF) is routinely used for mobilization of hematopoietic stem and progenitor cells preceding autologous transplantation after high-dose chemotherapy in hematologic malignancies. However, due to high mobilization failure rates, alternative mobiliza...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girbl, Tamara, Lunzer, Verena, Greil, Richard, Namberger, Konrad, Hartmann, Tanja Nicole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Transplantation and Cellular Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215600/ https://www.ncbi.nlm.nih.gov/pubmed/24673458 http://dx.doi.org/10.1111/trf.12632

Ejemplares similares

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

P1378: PLERIXAFOR AND GRANULOCYTE COLONY STIMULATING FACTOR FOR POOR MOBILIZERS IN PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE INSTITUTION STUDY
por: El Cheikh, J., et al.
Publicado: (2022)

Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
por: Avramova, Boryana E, et al.
Publicado: (2011)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Prognostic Value of Hematogones in Patients With Hematopoietic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
por: Mori, Hirotaka, et al.
Publicado: (2023)

Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
por: Masetti, Riccardo, et al.
Publicado: (2023)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma
por: Pelus, Louis M, et al.
Publicado: (2011)

Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease
por: Page, Kristin M., et al.
Publicado: (2022)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
por: Miyata, Masahiro, et al.
Publicado: (2023)

Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure
por: Sabulski, Anthony, et al.
Publicado: (2021)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant
por: Wu, Natalie L., et al.
Publicado: (2022)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Next-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantation
por: Liang, Emily C., et al.
Publicado: (2023)

Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis
por: Taylor, Mallory R., et al.
Publicado: (2023)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes
por: Kim, Yae-Jean, et al.
Publicado: (2022)

Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation
por: Petersdorf, Effie W., et al.
Publicado: (2023)

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant
por: Pérez-Valencia, Amanda Isabel, et al.
Publicado: (2022)

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic
por: Devine, Steven M., et al.
Publicado: (2023)

Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
por: Kanaan, Sami B., et al.
Publicado: (2023)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Selected memory T cells infused post–haploidentical hematopoietic stem cell transplantation persist and hyperexpand
por: van Beek, Jasper J. P., et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

Variable CD34(+) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic
por: Purtill, Duncan, et al.
Publicado: (2020)

Risk factors for seasonal human coronavirus lower respiratory tract infection after hematopoietic cell transplantation
por: Ogimi, Chikara, et al.
Publicado: (2021)

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
por: Ren, Xiying, et al.
Publicado: (2021)

Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation
por: Blair, Lily M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s07ei8kpg001id467kif3qg7gn